Archive for November, 2022
Why I Believe Northwest Biotherapeutics Has Been and Continues to be the Subject of a Powerful Stock Manipulation Scheme
DCVax-L Impressive Phase 3 Results Are Validated by Independent, Expert Scientists and Physicians; Supports Strong Upward Stock Move The final results of the phase 3 trial of DCVax-L were first released on May 10 at the New York Academy of Sciences conference. They were extremely encouraging showing that glioblastoma (GBM) patients treated with DCVax-L plus […]
Explanation of How Adam Feuerstein Has Egregiously Misrepresented the Results of the Phase 3 Trial of DCVax-L
Executive Summary I have tried to make this report as short and readable as possible so that in many cases I provide links to a previous article I have written or other pertinent data, rather than recreating the information in this report. So, you will find lots of links. The intent is to give the […]
Northwest Biotherapeutics; JAMA Oncology A Publication Journal of the American Medical Association Publishes Peer Reviewed Article on DCVax-L (murcidencel).
Overview This article puts into perspective the importance of a peer reviewed article on the Phase 3 Trial of murcidencel (better known as DCVax-L) that was published today in JAMA Oncology, A publication of the Journal of the American Medical Association. This is a landmark event in which independent experts in an exhaustive process (which […]
Northwest Biotherapeutics’ Day Has Come at Last
I’m Back Earlier this year I decided to end subscriptions to SmithOnStocks.com. Researching and writing articles on biotechnology companies required a significant amount of time and effort that detracted from other things that I wanted to do. I am very curious by nature and get genuinely excited when learning new things. My interests include biology, […]